BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kosmalski M, Mokros Ł, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent Eur J Immunol 2018;43:231-9. [PMID: 30135638 DOI: 10.5114/ceji.2018.77395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 El-Aziz RA, Alnaggar ARLR, Mohamed Nabih MI, Ali SM, Khattab H, El-Atty SA. Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. Clin Exp Hepatol 2020;6:28-34. [PMID: 32166121 DOI: 10.5114/ceh.2020.93053] [Reference Citation Analysis]
2 Zheng Z, Li Y, Fan S, An J, Luo X, Liang M, Zhu F, Huang K. WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPKβ1. Cell Death Dis 2021;12:228. [PMID: 33658485 DOI: 10.1038/s41419-021-03536-8] [Reference Citation Analysis]
3 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Guo T, Dai Z, You K, Battaglia-Hsu SF, Feng J, Wang F, Li B, Yang J, Li Z. S-adenosylmethionine upregulates the angiotensin receptor-binding protein ATRAP via the methylation of HuR in NAFLD. Cell Death Dis 2021;12:306. [PMID: 33753727 DOI: 10.1038/s41419-021-03591-1] [Reference Citation Analysis]
5 Amanatidou AI, Dedoussis GV. Construction and analysis of protein-protein interaction network of non-alcoholic fatty liver disease. Comput Biol Med 2021;131:104243. [PMID: 33550014 DOI: 10.1016/j.compbiomed.2021.104243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Khiatah B, Nasrollah L, Covington S, Carlson D. Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report. World J Clin Cases 2021; 9(6): 1455-1460 [PMID: 33644215 DOI: 10.12998/wjcc.v9.i6.1455] [Reference Citation Analysis]
7 Lv Y, Patel N, Zhang HJ. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Rev Gastroenterol Hepatol 2019;13:1169-80. [PMID: 31774328 DOI: 10.1080/17474124.2019.1697231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Piguet AC, Guarino M, Potaczek DP, Garn H, Dufour JF. Hepatic gene expression in mouse models of non-alcoholic fatty liver disease after acute exercise. Hepatol Res 2019;49:637-52. [PMID: 30811073 DOI: 10.1111/hepr.13323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Escutia-Gutiérrez R, Rodríguez-Sanabria JS, Monraz-Méndez CA, García-Bañuelos J, Santos-García A, Sandoval-Rodríguez A, Armendáriz-Borunda J. Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Sci Rep 2021;11:11709. [PMID: 34083664 DOI: 10.1038/s41598-021-91187-2] [Reference Citation Analysis]
10 Shafiha R, Bahcivanci B, Gkoutos GV, Acharjee A. Machine Learning-Based Identification of Potentially Novel Non-Alcoholic Fatty Liver Disease Biomarkers. Biomedicines 2021;9:1636. [PMID: 34829865 DOI: 10.3390/biomedicines9111636] [Reference Citation Analysis]
11 Huang Z, Wu LM, Zhang JL, Sabri A, Wang SJ, Qin GJ, Guo CQ, Wen HT, Du BB, Zhang DH, Kong LY, Tian XY, Yao R, Li YP, Liang C, Li PC, Wang Z, Guo JY, Li L, Dong JZ, Zhang YZ. Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways. Hepatology 2019;70:1099-118. [PMID: 30820969 DOI: 10.1002/hep.30597] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
12 Tan J, Xu J, Wei G, Zhang L, Sun L, Wang G, Li F, Jiang F. HNF1α Controls Liver Lipid Metabolism and Insulin Resistance via Negatively Regulating the SOCS-3-STAT3 Signaling Pathway. J Diabetes Res 2019;2019:5483946. [PMID: 31223625 DOI: 10.1155/2019/5483946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]